Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 27;9(3):e1277.
doi: 10.1002/lio2.1277. eCollection 2024 Jun.

Assessment of chronic rhinosinusitis with nasal polyps: Development of the Nasal Polyp Patient Assessment Scoring Sheet tool

Saad Alsaleh  1 , Nehal Kamal  2 , Claire Hopkins  3 , Hussain Al Rand  4 , Osama A Marglani  5   6 , Abdulmohsen Alterki  7   8 , Omar Abu Suliman  9 , Talal Alandejani  10 , Reda Kamel  11 , Rashid Al Abri  12 , Naif H Alotaibi  13 , Ahmad Al Amadi  14 , Abdullah Bahakim  15 , Joseph K Han  16 , Amin Javer  17 , Ahmad R Sedaghat  18 , Philippe Gevaert  19
Affiliations

Assessment of chronic rhinosinusitis with nasal polyps: Development of the Nasal Polyp Patient Assessment Scoring Sheet tool

Saad Alsaleh et al. Laryngoscope Investig Otolaryngol. .

Erratum in

Abstract

Background: Chronic rhinosinusitis (CRS) is a heterogeneous disorder with a wide range of validated subjective and objective assessment tools to assess disease severity. However, a comprehensive and easy-to-use tool that integrates these measures for determining disease severity and response to treatment is still obscure. The objective of this study was to develop a standardized assessment tool that facilitates diagnosis, uniform patient monitoring, and comparison of treatment outcomes between different centers both in routine clinical practice and in research.

Methods: To develop this tool, published literature on assessment tools was searched on various databases. A panel of 12 steering committee members conducted an advisory board meeting to review the findings. Specific outcome measures to be included in a comprehensive assessment tool and follow-up sheet were then collated following consensus approval from the panel. The tool was further validated for content and revised with expert recommendations to arrive at the finalized Nasal Polyp Patient Assessment Scoring Sheet (N-PASS) tool.

Results: The N-PASS tool was developed by integrating the subjective and objective measures for CRS assessment. Based on expert opinions, N-PASS was revised to be used as an easy-to-use guidance tool that captures patient-reported and physician-assessed components for comprehensively assessing disease status and response to treatment.

Conclusion: The N-PASS tool can be used to aid in the diagnosis and management of CRS cases with nasal polyps. The tool would also aid in improved monitoring of patients and pave the way for an international disease registry.

Level of evidence: Oxford Level 3.

Keywords: EPOS; SinoNasal Outcome Test; assessment; biologics; consensus; control; diagnosis; eosinophilic; nasal polyps; outcome measure; rhinosinusitis; scoring sheet; sinusitis; type 2.

PubMed Disclaimer

Conflict of interest statement

Saad Alsaleh received honoraria from Sanofi and GSK for lectures and advisory board activities. Nehal Kamal, BS Pharm, is an employee of Sanofi and may hold shares and/or stock options in the company. Claire Hopkins has done advisory board work for Sanofi, GSK, Lilly, and Astra Zeneca. Omar Abu Suliman has been involved in advisory board work for Sanofi and GSK. Naif H. Al‐Otaibi has received advisory board fees and honoraria for lectures from Sanofi and GSK. Joseph K. Han is a research consultant for Sanofi Regeneron GSK AZ and Genentech. Amin Javer is a speaker/consultant for GSK, Sanofi Regeneron, iView Therapeutics, and SaNOtize. Ahmad R. Sedaghat has been involved in research funding and advisory board participation for Sanofi/Regeneron and GSK. Philippe Gevaert declares he has received lecture fees and/or participation at expert board meetings from ALK‐Abelló, Argenx, AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Regeneron, Roche, Sanofi, and Stallergenes Greer. The remaining authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Flow diagram to depict the process of N‐PASS tool development. N‐PASS, Nasal Polyp Patient Assessment Scoring Sheet.
FIGURE 2
FIGURE 2
The N‐PASS tool. N‐PASS, Nasal Polyp Patient Assessment Scoring Sheet.
FIGURE 3
FIGURE 3
The N‐PASS follow up tool. N‐PASS, Nasal Polyp Patient Assessment Scoring Sheet.
FIGURE 4
FIGURE 4
(A) The N‐PASS tool for patient's response. (B) The N‐PASS follow up tool for patient's response. N‐PASS, Nasal Polyp Patient Assessment Scoring Sheet.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Sedaghat AR. Chronic rhinosinusitis. Am Fam Physician. 2017;96(8):500‐506. - PubMed
    1. Viskens AS, Wils T, Van Bulck P, Cools L, Vanderveken O, Hellings PW. Multiple reasons underlaying uncontrolled disease in the majority of chronic rhinosinusitis patients. Front Allergy. 2022;3:1048385. doi:10.3389/falgy.2022.1048385 - DOI - PMC - PubMed
    1. Fokkens WJ, Lund VJ, Hopkins C, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58(suppl S29):1‐464. - PubMed
    1. Fokkens WJ, Lund VJ, Mullol J, et al. European position paper on rhinosinusitis and nasal polyps 2012. Rhinol Suppl. 2012;23:3‐298. - PubMed
    1. Oykhman P, Paramo FA, Bousquet J, Kennedy DW, Brignardello‐Petersen R, Chu DK. Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: a systematic review and network meta‐analysis. J Allergy Clin Immunol. 2022;149(4):1286‐1295. doi:10.1016/j.jaci.2021.09.009 - DOI - PubMed

LinkOut - more resources